Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Profit After Tax (2017 - 2025)

Aclaris Therapeutics has reported Profit After Tax over the past 9 years, most recently at -$19.8 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$19.8 million for Q4 2025, up 79.5% from a year ago — trailing twelve months through Dec 2025 was -$64.9 million (up 50.84% YoY), and the annual figure for FY2025 was -$64.9 million, up 50.84%.
  • Profit After Tax for Q4 2025 was -$19.8 million at Aclaris Therapeutics, down from -$14.6 million in the prior quarter.
  • Over the last five years, Profit After Tax for ACRS hit a ceiling of -$1.5 million in Q4 2023 and a floor of -$96.6 million in Q4 2024.
  • Median Profit After Tax over the past 5 years was -$19.9 million (2022), compared with a mean of -$23.2 million.
  • Biggest five-year swings in Profit After Tax: skyrocketed 94.6% in 2023 and later crashed 6375.65% in 2024.
  • Aclaris Therapeutics' Profit After Tax stood at -$22.8 million in 2021, then dropped by 21.18% to -$27.6 million in 2022, then skyrocketed by 94.6% to -$1.5 million in 2023, then crashed by 6375.65% to -$96.6 million in 2024, then soared by 79.5% to -$19.8 million in 2025.
  • The last three reported values for Profit After Tax were -$19.8 million (Q4 2025), -$14.6 million (Q3 2025), and -$15.4 million (Q2 2025) per Business Quant data.